Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
V930 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | V930 |
| 2 | EXPERIMENTAL | V932 |
| Name | Type | Description |
|---|---|---|
| V930 | BIOLOGICAL | V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses. |
| V932 | BIOLOGICAL | V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection). |
Inclusion Criteria: * Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment * Patient must not be pregnant 3 days prior to enrollment Exclusion Criteria: * Patient is currently participating or has participated in a study with an investig...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
V930 is an investigational monoclonal antibody developed by Merck & Company, Inc. (MRK) for oncology. It is being studied in patients with cancers that express HER-2 and/or CEA, which are biomarkers used to select patients for treatment. V930 remains in Phase 1 clinical development and is not approved for any use.
V930 is being studied for the treatment of cancers expressing HER-2 and/or CEA. These biomarkers are used to select patients whose tumors carry one or both of these targets. The program is in Phase 1 testing, so V930 is investigational and has no approved indication.
V930 is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the clinical program studying V930 in biomarker-selected cancer patients.
V930 is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA for any indication. The Phase 1 program has been completed, with no active trials currently listed.
V930 has been studied in two completed Phase 1 trials. NCT00250419 was the first-in-man study in cancers expressing HER-2 and/or CEA, enrolling 26 patients. NCT00647114 tested V930/V932 in patients with cancers expressing HER-2 and/or CEA and enrolled 41 patients.